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ABSTRACT
Human gliomas harbour cancer stem cells (CSCs) that evolve along the course of 
the disease, forming highly heterogeneous subpopulations within the tumour mass. 
These cells possess self-renewal properties and appear to contribute to tumour initiation, 
metastasis and resistance to therapy. CSC cultures isolated from surgical samples are 
considered the best preclinical in vitro model for primary human gliomas. However, it 
is not yet well characterized to which extent their biological and functional properties 
change during in vitro passaging in the serum-free culture conditions. Here, we 
demonstrate that our CSC-enriched cultures harboured from one to several CSC clones 
from the human glioma sample. When xenotransplanted into mouse brain, these cells 
generated tumours that reproduced at least three different dissemination patterns found 
in original tumours. Along the passages in culture, CSCs displayed increased expression 
of stem cell markers, different ratios of chromosomal instability events, and a varied 
response to drug treatment. Our findings highlight the need for better characterization 
of CSC-enriched cultures in the context of their evolution in vitro, in order to uncover 
their full potential as preclinical models in the studies aimed at identifying molecular 
biomarkers and developing new therapeutic approaches of human gliomas.
INTRODUCTION
Glioblastoma (GBM) is the most common and 
devastating brain tumor in human adults [1], with an 
incidence ranging from 0.59 to 3.69 per 100 000 persons/
year [2]. The average survival does not exceed 15 months 
even after extensive surgery followed by radiotherapy 
alone or in combination with Temozolomide treatment 
[3-5], and just 0.05% to 4.7% of patients survive 5 years 
after diagnosis [6, 7].
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High lethality of GBM might be partly attributed 
to a small population of tumour cells, termed Cancer 
Stem Cells (CSCs), which drive tumour initiation and 
maintenance [8-11]. Current approaches to treat GBM 
patients have little success, possibly due to the fact that 
the CSC subpopulation is refractory to both chemo- and 
radiotherapy. Growing evidence points to CSCs as a more 
reliable preclinical GBM model than traditional cancer cell 
lines; therefore, many efforts have been made to isolate 
and culture CSCs in order to study their contribution to 
the tumorigenic processes, as well as to identify new 
therapeutic targets and biomarkers for diagnostics, 
prognostics, GBM stratification, treatment selection, and 
follow-up response to therapy.
CSCs display intra- and inter-tumour heterogeneity 
[12, 13], carry genomic and genetic alterations found 
in the original tumour and phenocopy their critical 
histopathological features when grown in serum-free 
media [14]. Under these culture conditions, CSC gene 
expression patterns resemble the original tumour more 
closely than those of other established tumour cell 
lines [15, 16]. Comparative analysis of different CSC 
collections reveals at least two different CSC subtypes: 
the first one with a proneural-like phenotype, and a 
highly invasive behaviour, and the second one with 
a mesenchymal-like phenotype and a nodular pattern 
with minimal invasiveness [17-19]. In addition, mRNA 
expression profiling and cytogenetic analysis of 48 
glioma surgical samples from The Cancer Genome Atlas 
Research Network (TCGA) [20, 21], suggests there are 
four different CSC subtypes: proneural, mesenchymal, 
classical and neural [22], thus emphasizing the value of 
CSCs as preclinical models for GBMs.
CSCs are dynamic systems susceptible to evolution 
in culture, resulting in molecular alterations not found in 
the original tumours [19]. Their response to functional 
assays, such as tumour cell migration and dissemination, 
proliferation or drug sensitivity, might thus experience 
important changes as they evolve, affecting the 
reproducibility of the results as well as their capacity to 
model the original tumours. Therefore, in order to define 
the best biologically and clinically relevant conditions for 
a given experiment, the study of GBM CSC phenotypic 
and molecular dynamic in culture is essential.
Here, we present a collection of results showing 
that serum-free media selected CSC-enriched cultures 
ranging from homogeneous to quite heterogeneous 
populations from the original tumour. As they evolved in 
vitro, these cells displayed increasing stemness marker 
expression, as well as different ratios of chromosomal 
instability events. They reproduced at least three different 
dissemination patterns found in the original tumours, but 
exhibited irregular response to drugs between passages. 
Our findings highlight the need to characterize a large 
number of CSC-enriched cultures, both in the context of 
their original tumours and their in vitro evolution, in order 
to take full advantage of these preclinical tumour models 
for developing new therapeutic approaches.
RESULTS
Isolation and characterization of CSC cultures 
from human surgical samples
In order to examine the stability of CSC cultures, 
together with live-cell functions, we first isolated eleven 
CSC-enriched cultures derived from fresh surgical 
human GBM samples and cultured them under serum-
free conditions [23]. As such, they grew as expandable 
sphere-like cultures showing different growing features 
under the optical microscope, based on which they 
were grouped into three clusters (Supplementary Table 
S1). One representative culture for each cluster was 
chosen for further analysis, and their CSC properties 
were characterized within the first 2 passages (see 
Supplementary Section). GBM18 grew as spheres attached 
to the surface that eventually detached (Figure 1A, i), 
GBM27 grew as spheres in suspension (Figure 1B, i) 
and GBM38 grew as an attached monolayer of cells in 
combination with spheres that eventually detached from 
the plate (Figure 1C, i). Then, with the aim of studying 
the evolution of CSCs in vitro right after their isolation, 
we subcultured them for up to 20 passages (18 months) 
without freeze-thaw cycles (Supplementary Figure S5).
Cell morphology of CSCs and tumourspheres 
remains stable along passages
We first examined the sphere surface and observed 
that all three CSC cultures displayed different cellular 
projection patterns that remained unchanged for all 
passages studied (Figure 1A, ii, 1B, ii and 1C, ii). 
Afterwards, we wondered whether the cell organization 
within the spheres also followed reproducible patterns. 
Interestingly, for all three CSC cultures, we found the 
presence of extracellular matrix (Figure 1A, iii and iv, 
1B, iii and iv and 1C, iii and iv) and, along the number 
of passages, we observed an increasing number of spheres 
displaying wider intercellular space and a higher number 
of cell membrane projections, some of which interlaced, 
increasing the membrane surface per cell and contributing 
to the maintenance of the sphere architecture (Figure 1D, i).
Next, the spheres were processed to carry out a 
comparative study of cell morphology intra- and inter-
CSC culture. Serial semithin sections showed significant 
inter-CSC culture differences but a high grade of intra-
CSC culture homology. We observed that the presence 
of multilobular and polymorphic nuclei was a common 
feature for all of them. Additionally, dividing cells 
were observed in both the peripheral regions and the 
center of the tumourspheres (Supplementary Figure S6). 
Ultrathin sections revealed that most cells displayed 
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the presence of differential inter-CSC culture abnormal 
inclusions. GBM18 showed inclusions compatible with 
polysaccharide deposits (Figure 1A, v), GBM27 showed 
an important number of electron dense inclusions (Figure 
1B, v) and GBM38 a combination of polysaccharide, 
electron dense and lipid inclusions (Figure 1C, v). Finally, 
we also observed the alteration of the mitochondrial 
architecture along the passages (Figure 1A, vi, 1B, vi, 
Figure 1: Neurosphere architecture and cell morphology analysis of GBM18, GBM27 and GBM38 CSC-enriched 
cultures. A. GBM18 neurosphere morphology under the OM (i), SEM (ii) and TEM (iii-vi). Black arrow shows extracellular matrix 
(iv), white asterisk shows clear cytoplasm cells (iii) and black asterisk shows representative polysaccharide intracellular deposits (5). 
B. GBM27 neurosphere morphology under the OM (i), SEM (ii) and TEM (iii-vi). Black arrow shows extracellular matrix (iv), white 
asterisk shows clear cytoplasm cells (iii) and black asterisk shows representative electro-dense intracellular deposits (v). C. GBM38 
neurosphere morphology under the OM (i), SEM (ii) and TEM (iii-vi). White arrow shows extracellular matrix (iv) and representative 
lipid drops (v). Black arrow shows representative electro-dense intracellular deposits (v). White asterisk shows clear cytoplasm cells and 
black asterisk shows representative polysaccharide intracellular deposits (iii). D. Highlighted differences observed along the GBM18, 
GBM27 and GBM38 passages in culture: neurosphere architectural reorganization (i), mitochondrial crest architectural loss (ii) and double 
membrane structures (iii).
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1C, vi and 1D, ii) and the presence of double membrane 
structures in late passages (Figure 1D, iii). Interestingly, 
the cell morphology remained mostly unchanged for all 
three CSC cultures along the passages.
CSC-enriched cultures increase their stemness 
stage along the passages
Once we have discarded relevant changes in cell 
morphology within the tumorspheres, we looked into the 
mRNA expression of CSC markers. We found that cells 
in late passages from GBM18, GBM27 and GBM38 
expressed higher mRNA levels of CD133 and CD44 
while those of SSEA1 remained unchanged (Figure 2A). 
Consistently, when we analysed the mRNA expression 
of stem cell markers such as OCT3/4, BMI and SOX2 we 
found increasing values in late passages with the only 
exception of SOX2 for GBM38, whose expression level 
remained low and even along the passages. Additionally, 
the mRNA expression level of adult neural stem cell 
Figure 2: Gene expression analysis at early and late passages of CSC-enriched cultures. A. Cancer Stem Cell 
markers. B. Stemness markers. C. Differentiation markers. Keywords: black columns represent early passages; white columns represent 
late passages; for every comparative analysis, the sample with lower mRNA gene expression is given the value 1. Error bar represents 
Standard Deviation. *: P ≤ 0.05; **: P ≤ 0.01 and ***: P ≤ 0.001.
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markers, such as NESTIN and MELK, also increased in 
late passages, while the expression of TERT remained high 
and unchanged (Figure 2B). As the results suggested an 
increased stemness stage of CSC-enriched cultures along 
the passages, we also looked into the mRNA expression of 
differentiation markers for the three main neural lineages. 
We observed that astrocyte markers (GFAP and S100β) 
remained unchanged along the passages for all three 
CSC-enriched cultures studied. The mRNA expression of 
neuronal markers remained equal for GBM18 and GBM27 
with a little increase of β-III-Tubulin in late passages 
of GBM38. Moreover, we did not observe significant 
changes in transcript levels of the early oligodendrocyte 
marker PDGFRa, while CNPase increased in late passages 
for GBM18 and GBM38 (Figure 2C).
Chromosomal instability collaborates with 
in vitro evolution of CSC-enriched cultures
Chromosomal instability is a hallmark of tumor 
cells, including gliomas, and the main cause of genomic 
alterations throughout the course of the disease. In order 
to evaluate the occurrence of genomic alterations in CSCs 
isolated from surgical samples, over their passages in 
culture, we carried out sequential Comparative Genomic 
Hybridization (CGH) assays on GBM18, GBM27 and 
GBM38. First, we wondered whether the chromosomal 
instability might be generated by the isolation and culture 
procedures or due to an inherent feature of CSCs. To 
rule out the first possibility, we set out to investigate the 
presence of genomic alterations in Neural Stem Cells 
(NSCs) isolated from surgical samples of human adult 
brain - normal counterpart of CSCs - under the same 
isolation and culture procedures used for CSCs. The 
analysis of CGH data showed the absence of genomic 
alterations in NSCs along the first 7 passages, when the 
cells became senescent (Supplementary Figure S7). 
These results demonstrated that our isolation and culture 
procedures did not generate chromosomal instability 
in human adult NSCs displaying a normal genetic 
background.
Then, we focused on the analysis of CGH data from 
all three CSC-enriched cultures – GBM18, GBM27 and 
GBM38- at passages 1, 5, 7, 10, 15 and 20. As expected, 
we observed genomic alterations due to DNA losses and 
gains in all three CSC-enriched cultures. Interestingly, 
genomic alterations identified in GBM18 remained 
unchanged for all passages assayed while GBM27 and, 
to a greater extent, GBM38 displayed chromosomal 
instability events along the passages (Figure 3A-3C).
In general, DNA losses outnumbered gains in all 
three CSC-enriched cultures. GBM18 displayed genomic 
alterations in 17 somatic chromosomes, including 3 DNA 
gains in chromosomes 3, 7 and 20, and 25 DNA losses in 
15 different chromosomes (Figure 3A and Supplementary 
Table S4). GBM27 also displayed genomic alterations 
in 17 somatic chromosomes, including 11 gains in 
10 chromosomes, although the total number of gains 
came down to 6 after the first passage. Additionally, 
this CSC-enriched culture exhibited a total of 26 DNA 
losses in 11 chromosomes along the 20 passages; being 
chromosomes 10 and 19 the most affected, with 6 and 5 
DNA losses, respectively (Figure 3B and Supplementary 
Table S5). Finally, GBM38 displayed genomic alterations 
in all somatic chromosomes. We detected a total of 22 
DNA gains in 11 chromosomes, and 28 DNA losses in 
17 chromosomes, along all passages (Figure 3C and 
Supplementary Table S6).
Next, we wondered whether the most recurrent 
sites of DNA copy-number aberration described in 
glioma samples, containing a putative oncogene or 
tumor suppressor gene [24], might be also altered in 
CSC-enriched cultures. To address this question, we 
analysed the location of 19 statistically significant DNA 
gains and 20 DNA losses identified previously from 
543 GBM solid samples by TCGA [24] (Supplementary 
Table S7). GBM18 displayed just 3 DNA gains, all of 
them at chromosome 7, including the oncogenes EGFR, 
CDK6 and MET, and 2 DNA losses including AKT1 
and AKT3, within the set of recurrent DNA gains. On 
the contrary, this CSC-enriched culture showed 10 
DNA losses (50%) and no DNA gains within the set of 
recurrent DNA losses (Figure 3A and Supplementary 
Tables S4 and S7). Interestingly, GBM27 and GBM38 
displayed changes on DNA gains and losses throughout 
the passages, affecting the location of both oncogenes 
and tumor suppressors. GBM27 showed DNA gains 
affecting the location of 14 genes within the set of 
recurrent DNA gains at first passage, although half of 
them involved less than 50% of the cells. However, 
after the fifth passage, many DNA gains disappeared, 
remaining those that affected the location of MYCN, 
SOX2, EGFR, CDK6, MET and GRB2. Nonetheless, after 
the tenth passage, MYCN and GRB2 DNA sequence gains 
persisted in less than 50% of cells. Unexpectedly, this 
CSC-enriched culture displayed 6 DNA gains and just 
3 DNA losses within the set of recurrent DNA losses at 
first passage, although the DNA gains reduced to 5 after 
the fifth passage, affecting the location of LSAMP, 3q29 
and NF1, which actually involved less than 50% of cells 
after the tenth passage. DNA losses affecting the location 
of CDKN2A/B, PTEN and 19q13.33, for all passages, and 
QKI, 10q26.3 and 15q14, in less than 50% of the cells, 
after the tenth passage were also detected (Figure 3B 
and Supplementary Tables S5 and S7). Finally, GBM38 
showed DNA losses affecting chromosomes 4 and 12 in 
all passages, and chromosome 17 after the fifth passage, 
within the set of recurrent DNA gains. These DNA losses 
matched the location of FGFR3, PDGFRa, CCND2, 
CDK4, MDM2 and GRB2. Surprisingly, DNA sequence 
gains affecting the location of EGFR, CDK6 and MET 
at chromosome 7 disappeared after the tenth passage, 
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while others affecting AKT3 and MDM4 at chromosome 
1 appeared from the fifth passage on. Consistent with 
this, the same variability was observed within the set 
of recurrent DNA losses. We detected 4 DNA gains at 
the first passage in chromosomes 3, 15 and 22, all of 
them affecting less than 50% of the cells. However, 3 
of these DNA gains disappeared after the fifth passage 
and the last one after the tenth passage. Interestingly, 2 
new DNA gains, affecting chromosome 1, appeared at 
passage 5 in 100% of the cells and remained along the 20 
passages under study. We also observed the presence of 
4 DNA losses in all passages, affecting the chromosome 
9 (CDKNA/B), 10 (PTEN and 10q26.3) and 14 (NPAS3). 
Surprisingly, the DNA sequences gained at the first 
passage, affecting chromosome 22 in less than 50% of 
the cells, were consistently lost in 100% of the cells 
from the fifth passage on, and the same happened for 
the 2 DNA gains affecting the chromosome 3 at the first 
passage, which turned out to be lost at the last passage. 
Finally, to add on the high chromosomal instability of 
this CSC-enriched culture, we found 2 more DNA losses, 
affecting the chromosome 13 (RB1 and 13q22.1) in less 
than 50% of the cells, between the passages 7 and 10 
(Figure 3C and Supplementary Tables S6 and S7).
Figure 3: Graphical representation of chromosomal imbalances detected in GBM18, GBM27 and GBM38 CSC-
enriched cultures along the 20 first passages in culture after isolation from surgical samples. A. GBM18. B. GBM27. 
C. GBM38. The X-axis represents the chromosomes, while the Y-axis represents the normalized log2 Cy5(CSC)/Cy3(healthy control) 
fluorescence intensity thresholds -1 (loss(red)) and 1 (gain (blue)), respectively. The genes AKT3, QK1, EGFR, RB1, AKT1 and TP53, 
frequently altered by DNA gains or losses in human gliomas, are shown as ideograms at passage 1 and 20. The clear boxes indicate the 
location of the gene. Blue represents DNA gains and red DNA losses.
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CSC proliferation and duplication times display 
fluctuations along the passages
We next wondered whether the observed changes in 
morphology, chromosomal instability and differentiation 
state along the passages in culture, might influence the 
proliferation ratio of CSC-enriched cultures. To address 
this question, we carried out viability assays with early and 
late passages cultured in vitro for up to 5 days. In general, 
we found no significant differences in the percentage of 
viable cells between early and late passages of GBM27 
and GBM38. Interestingly, we did observe significant 
differences between early and late passages of GBM18 
(P < 0.01) (Figure 4A). GBM27 displayed the higher 
duplication time followed by GBM18 and GBM38, which 
showed the highest proliferation rate in vitro (Figure 4B). 
Then, we wanted to know whether the proliferation rate 
in vitro correlated with survival of mouse models of brain 
tumor xenotransplanted with these CSCs. Consistently, we 
found that the overall survival of xenotransplanted mice 
with GBM18 and GBM38 was quite similar, around 100 
days, while those mice xenotransplanted with GBM27 
displayed longer overall survival with an average of 220 
days (Figure 4C).
In vivo migration and dissemination patterns of 
CSCs remain unchanged along passages
To evaluate the ability of these CSC-enriched 
cultures to recapitulate the original tumor features, we 
carried out orthotopic transplantations within the striatal 
brain of adult nude mice. Staining with anti-human 
Vimentin, to expose human cells, revealed the in vivo 
migration and invasion capacity of these three CSC-
enriched cultures. At the time of diagnosis, GBM18 and 
GBM27 were clinically described as highly disseminating, 
while GBM38 was described as nodular (Figure 5A, 1-3). 
Consistent with clinical description, GBM18 formed a 
nodular-like tumor mass; however, the nodular boundaries 
were not well defined. The cells migrated out of the 
nodular tumor mass and invaded the neighbouring tissues, 
reaching the contralateral hemisphere at both early and 
late passages (Figure 5A, 1). Interestingly, GBM27 CSCs 
disseminated through the mouse brain and invaded the 
contralateral hemisphere at both early and late passages 
(Figure 5A, 2). On the contrary, GBM38 CSCs remained 
within the ipsilateral hemisphere forming a nodular-
like tumor mass, with well-defined boundaries, also at 
both early and late passages (Figure 5A, 3). We found 
GBM18 CSCs surrounding blood vessels in the striatum, 
but not GBM27 CSCs. Both GBM18 and GBM27 CSCs 
seemed to accumulate along the ventricular wall and 
use the myelin fiber tracks within the striatum and the 
corpus callosum to migrate (Figure 5 and Supplementary 
Figure S8). In order to find a molecular signature that 
explained this histological finding, we studied the mRNA 
expression of genes related to migration and invasiveness. 
Consistently, the mRNA expression of CD90, CD144, 
CD24, CD73 and OLIG2 was higher in GBM27 followed 
by GBM18 and GBM38. Interestingly, the expression 
levels of CD90, CD144, CD166, CD24 and CD73, were 
significantly increased in the late passages of GBM27, 
as well as OLIG2 to a lesser extent. Similar results were 
observed when we analysed CD90, CD24, CD73 and 
OLIG2 for GBM18 and CD166 and CD73 for GBM38. 
However, the higher mRNA expression of migration and 
invasiveness markers at late passages did not translate into 
an increased migration of CSCs in vivo (Figure 5B).
The CSCs response to drugs evolves in vitro
Once we confirmed that all CSC-enriched cultures, 
regardless the passage in culture, reproduced the migration 
and dissemination patterns in vivo, we wanted to know 
whether the time in culture influenced their sensitivity to 
a panel of drugs currently used in both clinical trials and 
clinical practice against GBM. To address this question, 
we carried out functional viability assays with three 
different early and late passages for all CSC-enriched 
cultures (Figure 6). The IC50 as well as the percentage 
of cell survival at 10 µM were calculated by lineal 
interpolation to compare drug sensitivity between early 
and late passages. We found that all three CSC cultures 
showed significant differences between early and late 
passages in both the IC50 and the viability at 10 µM for at 
least 20% of the assayed drugs. Interestingly, late passages 
Figure 4: Viability of early and late passages of CSC-enriched cultures and average survival of mouse models of their 
respective brain tumor xenotransplants. A. Viability assay for early and late passages of GBM18, GBM27 and GBM38. B. Duplication 
time for early and late passages of GBM18, GBM27 and GBM38. C. Kaplan-Meier survival curves for mice xenotransplanted with 
GBM18, GB27 and GBM38.
Oncotarget65895www.impactjournals.com/oncotarget
Figure 5: Brain dissemination patterns of early and late CSCs isolated from human samples. A. MRI from the original tumor 
and mouse model of brain tumor xenotransplanted with GBM18 (A1), GBM27 (A2) and GBM38 (A3) at early and late passages. GBM18 
and GBM27 are clinically defined as highly disseminated while GBM38 as nodular. Squared regions are shown at higher magnification. 
B. Gene expression analysis of migration and invasiveness markers at early and late passages of CSC-enriched cultures. Keywords: black 
columns represent early passages; white columns represent late passages; Error bar represents Standard Deviation. *: P ≤ 0.05; **: P ≤ 0.01 
and ***: P ≤ 0.001.
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were significantly more sensitive to cisplatin. In the same 
line, we observed that all three CSC cultures displayed 
higher sensitivity to drugs interfering with DNA synthesis 
at late passages, with the only exception of camptothecin 
for which GBM38 showed an IC50 at least 10 times higher 
at late passages. However, there were no differences 
between early and late passages when we assayed drugs 
that interfered with DNA repair. GBM18 and GBM27 
displayed sensitivity to taxol but there were important 
differences between both CSC cultures. While the IC50 
between early and late passages of GBM27 was quite 
similar, late passages of GBM18 displayed an IC50 more 
than 50 times lower than early passages. The three CSC 
cultures were sensitive to bortezomib; however, GBM27 
and GBM38 were significantly more sensitive at early 
passages. Then, we assayed a collection of drugs targeting 
growth factors and cell signalling pathways. We observed 
an IC50 more than 10 times lower at early passages of 
GBM18 for tipifarnib, desatinib and perifosine, and the 
opposite for vorinostat. GBM27 also displayed significant 
differences between late and early passages for perifosine, 
enzastaurin and tipifarnib. Finally, we found significant 
differences between early and late passages of GBM38 for 
PLX4032 and to a lesser extent for desatinib, perifosine, 
temsirolimus and Nutlin-3 (Figure 6).
DISCUSSION
The percentage of surgical samples from which we 
were able to isolate expandable CSC cultures, as well as 
the different growth patterns observed, is consistent with 
previous works [11, 17, 18]. These patterns apparently did 
not change along the passages when observed under the 
OM. However, a closer analysis under the EM revealed 
morphological changes common to all three CSCs, as well 
as more specific features for each of them. For all analyzed 
CSC lines, TEM confirmed common architectural 
reorganization of spheres and a higher number of 
disrupted mitochondrial crests over the passages. The 
widening of intercellular spaces, together with the increase 
of membrane surface per cell, probably played a role in 
permitting the access of fresh nutrients to internal cells as 
well as the clearance of residual metabolites. Additionally, 
the alteration of mitochondrial cytoarchitecture might be 
Figure 6: Drug sensitivity panel of early and late CSCs isolated from human samples. For every CSC-enriched culture 
viability differences (% viability at late passages - % viability at early passages), as well as the viability at IC50 for early and late passages 
are shown. Keywords: red bars mean that early passages are more sensitive than late passages; blue bars mean that early passages are 
less sensitive than late passages; asterisks represent differences between early and late IC50 by * (one), ** (two) or *** (three) orders of 
magnitude.
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compatible with a progressive selection of glycolysis 
for glucose metabolism in vitro [25]. In this regard, the 
ability of CSCs isolated from human gliomas to use 
multiple pathways for energy production has been recently 
demonstrated, suggesting that CSCs might be refractory to 
treatments targeting individual metabolic pathways [26]. 
Moreover, we observed abnormal deposits of different 
types of macromolecules in all three CSC lines, probably 
as a result of altered metabolic pathways. In this regard, 
the deposit volume might be related to the differentiation 
stage; the clear cytosolic cells, found within the sphere, 
might thus correspond to the most undifferentiated CSC 
subpopulation. Interestingly, for all analysed CSC lines, 
the morphology of most cells within the spheres was 
highly homogeneous, which suggests a clonal origin of 
these cells.
In line with the homogeneous cell morphology 
within each CSC line, the analysis of specific molecular 
marker expression along the passages revealed a striking 
similarity between the analysed CSC lines. These results 
support the uniform presence of differentiated cells within 
the tumorspheres along the passages, and are consistent 
with the observation that cytosolic cells were overloaded 
with aberrant deposits. Furthermore, these results suggest 
a positive selection of CSCs with more prominent 
stemness stage. Our data thus confirm previous genomic 
analyses of CSC lines from different passages, which 
showed that CSC biological replicates grouped together 
when compared with other samples [15, 17, 27]. However, 
the relative expression of specific biomarkers between the 
passages has not been previously reported.
In the last few years, several groups have published 
a collection of data demonstrating the existence of 
intra-tumor heterogeneity in human glioblastoma [12, 
13, 28]. Consistent with these reports, we found that 
most chromosomal alterations affected 100% of the cell 
populations along the 20 passages after isolation. This 
finding, together with the morphologically homogeneous 
intra-tumoral CSCs, points to a clonal origin for the 
tumor cells present in primary cultures. Interestingly, our 
CGH analysis shows that the current protocols for CSC 
enrichment and culture, under serum-free conditions, 
randomly generate both homogeneous and heterogeneous 
populations of CSCs. We observed DNA gains, affecting 
less than 50% of the population, in the first passage of 
GBM27 and GBM38 cells that disappeared a few passages 
later, which might suggest the presence of clones less prone 
to survival or competitiveness than other clones in vitro. 
Additionally, DNA gains and losses affecting less than 
50% of the population showed up at different passages, 
and then either disappeared or remained underrepresented 
in the total population. Finally, for these two CSC-enriched 
cell lines, we also observed new DNA gains and losses, 
affecting 100% of the population, at different passages. On 
the contrary, CGH analysis showed no significant changes 
for the GBM18 homogenous population. All together, 
these results suggest that a heterogeneous population 
of CSC-enriched cell lines evolve in vitro as they do in 
vivo, although essential differences in microenvironment 
cues probably drive the evolution process in different 
directions. We found that CSC-enriched cultures displayed 
similar duplication times, meaning that the chromosomal 
instability and gene expression variability observed along 
passages did not translate into significant proliferation 
changes in vitro. Interestingly, mouse models of brain 
tumor xenotransplated with GBM27, that displayed 
the higher duplication time in vitro, showed the longest 
average survival. This result suggests a link between low 
proliferation in vitro and in vivo, however other parameters 
like the brain dissemination pattern, may also influence 
and more experiments with a higher number of CSC- lines 
will be needed to clarify this question.
Notably, the dissemination pattern of CSCs through 
the parenchymal brain in mice remained unchanged along 
the passages - resembling the original tumors -. This finding 
suggests the presence of either specific mutations or, most 
probably, coordinated molecular alterations, passed on 
from the original clone, responsible for the migration 
and dissemination. Consistently, other authors observed 
no changes in the dissemination patterns in vivo from 
different passages of CSCs [11, 17]. However, considering 
that CSCs also evolve in vitro, it is important to note that 
new alterations affecting essential molecules in migration 
pathways along the passages in vitro might modify the 
dissemination pattern in vivo. Importantly, we showed 
three different patterns of dissemination in vivo for CSCs 
isolated from human glioma samples. GBM27 displayed a 
highly disseminating pattern, longer overall survival and 
higher expression of OLIG2, consistent with the CSC type 
I described by Günther et al., and the proneural phenotype 
[29]. On the contrary, GBM18 and GBM38 displayed a 
nodular dissemination pattern and similar overall survival, 
which resemble the CSC type II , and the mesenchymal 
phenotype [16, 17, 29, 30]. However, GBM18 showed 
irregular boundaries, with cells migrating out of the main 
tumor mass, and significantly higher OLIG2 expression 
than GBM38. Therefore, the disseminated, nodular and 
semi-nodular preclinical in vivo models of GBM constitute 
three separated tumor behaviours that might need different 
therapeutical approaches.
Supporting the idea of in vitro evolution of CSC-
enriched cultures, we also observed significant variations 
in the IC50 for a number of drugs along the first 20 
passages in culture. These variations affected both homo 
(GBM18) and heterogeneous (GBM27 and GBM38) 
CSC-enriched cultures. The in vitro DNA gains and losses 
might thus not be enough to explain the drug-sensitivity 
variations, and genetic and/or epigenetic alterations along 
the passages might also play a role. These results suggest 
that reliable functional experiments need to be performed 
on well-characterized CSC-enriched cultures within a 
limited number of passages.
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Altogether, the CSC-enriched cultures from surgical 
samples are now the most reliable preclinical models of 
human high-grade glial tumors. However, these models 
are far from mimicking the original tumors. Indeed, 
these cultures evolve in vitro acquiring new features as a 
result of their intrinsic instability and microenvironment 
cues. Therefore, in order to take advantage of the whole 
potential of these preclinical tumor models to develop 
new therapeutic approaches, it will be essential to isolate 
a large number of CSC-enriched cultures and characterize 
them not only in the context of their original tumors but 
also their evolution in vitro.
MATERIALS AND METHODS
Isolation and culture of CSCs from human GBM 
samples
Cancer stem cells were isolated from human 
fresh GBM samples. Tissue samples were obtained 
from patients operated at the Neurosurgery department 
(Hospital la Fe, Spain). Permission to use this material 
was obtained from the ethical review board in Hospital 
la Fe and Principe Felipe Research Center, and written 
informed consent was obtained from patients. GBM CSCs 
and normal brain parenchyma cells were cultured in media 
containing: DMEM/F-12 (Gibco, 11039), Non Essential 
Amino Acids (10mM; Gibco, 11140), Hepes (1M; Gibco, 
15630), D-Glucose (45%; Sigma, G8769), BSA-F5 
(7,5%; Gibco, 15260), Sodium Pyruvate (100mM; Gibco, 
11360), L-Glutamine (200mM; Gibco, 25030), Antibiotic-
Antimycotic (100x; Gibco, 15240), N2 Supplement (100x; 
Gibco, 17502), Hydrocortisone (1μg/μl; Sigma, H0135), 
Tri-iodothyronine (100μg/ml; Sigma, T5516), EGF (25ng/
μl; Sigma, E9644), bFGF (25ng/μl; Sigma, F0291) and 
Heparin (1μg/μl; Sigma, H3393).
Tumorsphere morphological analysis
To evaluate possible changes in both the sphere 
architecture and cell morphology, we separated 12 spheres 
of 150 μm diameter from each CSC culture at different 
time points (Supplementary Figure S5) and further 
analysed them by optical microscopy (OM), Screening 
Electronic Microscopy (SEM) and Transmission 
Electronic Microscopy (TEM). Tumorspheres were 
fixed with 3.5% glutaraldehyde (Electron Microscopy 
Science, Hatfield, USA) for 1 h at 37°C. Afterwards, 
they were embedded in 3% agar drops and postfixed 
with 1% osmium tetroxide (Sigma), rinsed, dehydrated, 
and embedded in araldite (Durcupan, Sigma). For brain 
tissue analysis, at the appropriate time points, mice were 
deeply anesthetized with an intraperitoneal injection of 
Ketamine (100mg/kg) and Medetomidine (0,5mg/kg), 
and transcardially perfused with a 0.9% NaCl solution 
followed by a 2% paraformaldehyde/2.5% glutaraldehyde 
solution (PFA/GA, Electron Microscopy Sciences, 
Hatfield, PA) in PBS. Brains were removed, post-fixed in 
PFA/GA overnight and rinsed in cold PBS (5x10 min). 
After fixation, brains were cut into 200 μm sections on 
a vibratome (Leica VT-1000), rinsed, dehydrated and 
embedded in araldite (Durcupan, Sigma). For both 
types of samples, tumorspheres and brain tissue slides, 
semithin sections (1.5 μm) were cut with a diamond 
knife and lightly stained with 1% toluidine blue (Panreac, 
Barcelona, Spain). Semithin sections were detached from 
the glass slide by repeated freezing (liquid nitrogen) and 
thawing and re-embedded in an araldite block. The block 
with semithin sections was cut in ultrathin (0.05 μm) 
sections with a diamond knife, stained with lead citrate, 
and examined under a Tecnai Spirit Electron Microscope 
(FEI). Photographic images were taken with a Morada 
camera (Soft Image System, Munster, Germany).
RT and QRT-PCR
For RT-PCR, total RNA was isolated using RNeasy 
Mini or Micro kit (QIAGEN) following the manufacturer’s 
recommendations. One µg of RNA was used for cDNA 
synthesis (High-Capacity cDNA Reverse Transcription 
Kit; Applied BioSystems). Samples were amplified with 
specific primers and the Paq5000 polymerase (Stratagene), 
in a Mastercycler (Eppendorf). QRT-PCR was run in a 
LightCycler 480 Instrument (Roche). For each experiment, 
controls were performed in which reverse transcriptase 
was omitted from the cDNA reaction mixture and template 
DNA was omitted from the PCR mixture.
Cancer stem cell differentiation
Cells were plated for 10 days on 8-well chamber 
slides (Nalgene Nunc, 177402) coated with Matrigel 
Basement Membrane Matrix (2mg/ml; BD, 356234) in 
growth factor-free media supplemented with 10% FBS. 
Cells were then fixed in 4% paraformaldehyde.
Immunocytochemistry
Cells were fixed in 4% paraformaldehyde for 20 min, 
washed with PBS and incubated in 0.2% Triton X-100/PBS 
for 20min at 37ºC and 10min at RT. Cells incubated with 
BrdU were treated with 1N HCl for 30 min at 37ºC and 
neutralized in 0.1M borate buffer, pH 8.5 for 5min at RT. 
After treatment with 5% normal goat serum/0.1% Triton 
X-100/PBS for 15min, cells were incubated overnight at 
4ºC with the following primary antibodies: BrdU (mouse 
monoclonal, 1:100, Dako), GFAP (rabbit polyclonal, 
1:1000, Dako), SOX2 (goat, 1:50, Chemicon), Nestin 
(rat, 1:100, Chemicon), Tuj1 (chicken, 1:500, Sigma) and 
CNPase (mouse monoclonal, 1:400, Abcam). Cells were 
then incubated 1h with the corresponding Alexa Fluor 
conjugated secondary antibodies (1:500) and treated with 
DAPI (1:1000, Sigma) for 15min. Coverslips were mounted 
in Fluorsave Reagent (Calbiochem, 345789).
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Immunohistochemistry
Formalin-fixed paraffin-embedded sections were 
stained (as per the manufacturer’s staining protocol) with 
the Bond Polymer Refine Detection Kit on a Bond-max™ 
fully automated staining system (Leica Microsystems 
GmbH, Germany), using a mouse monoclonal 
antibody against human Vimentin (1:500, Santa Cruz 
Biotechnology).
Genomic DNA microarray
Genomic DNA was quantified by spectrophotometry 
(NanoDrop ND1000, NanoDrop Technologies, 
Wilmington, Delaware USA). Integrity of DNA was 
assessed by 0.8% agarose gel electrophoresis. Non-
amplification labeling of DNA (direct method) was 
obtained following the ‘Agilent Oligonucleotide Array-
Based CGH for Genomic DNA Analysis’ protocol 
Version 4.0 (Agilent Technologies, Palo Alto, California 
USA. p/n G4410-90010). 500 ng of experimental and 
pool female reference genomic DNA samples were 
fragmented in a restriction digestion step. Digestion 
was confirmed and evaluated by DNA 7500 Bioanalyzer 
assay. Cyanine 3-dUTP and cyanine 5-dUTP were used 
for fluorescent labeling of test and reference digested 
gDNAs respectively, using the ‘Agilent Genomic DNA 
Labeling Kit PLUS’ (Agilent p/n 5188-5309) according 
to the manufacturer’s instructions. Labeled DNA was 
hybridized with Human Genome CGH Microarray 44K 
(Agilent p/n G4426B-014950) containing 43,000+ 
coding and noncoding human sequences. Arrays were 
scanned in an Agilent Microarray Scanner (Agilent 
G2565BA) according to the manufacturer’s protocol and 
data extracted using Agilent Feature Extraction Software 
9.5.3.1 following the Agilent protocol CGH-v4_95_Feb07 
(‘Lowess Only’ normalization correction dye bias method 
instead of ‘Linear Only’) and the QC Metric Set CGH_
QCMT_Feb08.
Xenografts
All mouse experiments were approved by and 
performed according to the guidelines of the institutional 
animal care committee of Principe Felipe Research Center in 
agreement with the European Union and national directives. 
An average of 75.000 cells were stereotactically injected into 
the striatum of the right brain hemisphere (0 mm anterior 
and 2,5 mm lateral to the bregma; 3,5 mm intraparenchymal) 
of 9 week-old NUDE mice (Charles River Laboratories). 
Mice were euthanized when they presented neurological 
symptoms or a significant loss of weight.
MTS assays
The viability of early and late CSC-enriched culture 
in vitro as well as their sensitivity to different drugs 
was assessed using the MTS assay. Briefly, single-cell 
suspensions of CSCs were plated in a 96-well plate, 3000 
cells/well in a final volume of 80 μl/well. For the viability 
assay, they were allowed to grow up to 5 days and analyzed 
every 24 hours. For drug sensitivity assays, the cells were 
allowed to grow and to form spheres for 4 days. Cultures 
were then treated with 20 μl/well of media (control cells), 
vehicle (DMSO or water) or increasing concentrations 
of each drug for 72h. 20 μl/well of MTS (CellTiter 96 
AQueous One Solution Cell Proliferation Assay, Promega) 
was added to the culture media, incubated at 37ºC for 3 
hours and absorbance was measured at 490 nm. Sensitivity 
was assessed by comparing the absorbance values of 
drug-treated cells with vehicle-treated cells and with the 
absorbance values of control cells (untreated cells) for 
each treatment group. Each treatment group was repeated 
in quadruplicate and each experiment in duplicate. Lines 
were classified as sensitive if their viability decreased or 
remained unchanged compared with controls.
Statistical analysis
Statistical analyses were performed using a 2-tailed 
Student t test. Data are presented as means ± standard 
deviation and were calculated using the software package 
GraphPad Prism v. 5.0. Statistical values of p > 0.05 were 
not considered significant.
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